| Objective:Systematic review of autologous bone marrow stem cell transplantation for treatment efficacy and safety of severe lower limb ischemic disease. Methods: Computerized retrieval VIP (1990～2013), Cochrane Library, Springer Link (1990～2013), OVID (1990-2013), Pubmed (1990～2013), Science Direct (1990～2013), EBSCO (1990～2013), EMBASE (1990～2013) and other databases on autologous bone marrow stem cell related RCT study of severe lower limb ischemic disease transplantation therapy using RevMan5.2software Cochrane Centre provided statistical analysis of the data. Results:A total of12RCT studies, including510patients with critical limb ischemia. This study included articles on the subjective and objective endpoints for statistical analysis. Objective endpoints include including amputation rate, the rate of ulcer healing, not amputation free survival (AFS). Subjective indicators include:painless walking distance, ankle-brachial index (ABI) and transcutaneous oximetry (tcO2), pain scores were statistically significant (P<0.00001). Autologous bone marrow stem cell transplantation in the treatment of severe lower limb amputation rate between the experimental and control the amount of ischemia was significantly different [RR=0.58,95%CI (0.4～0.84), P=0.004]. Survival between the two groups was not statistically significant not amputation [RR=1.16,95%CI (0.92～1.48), P=0.22]. The incidence of ulcer healing both groups was statistically significant [RR=1.87,95%CI (1.49-2.36), P <0.00001]. Conclusion:During This meta-analysis reveals the potential possibility of autologous bone marrow stem cell transplantation for severe lower limb ischemic disease, and is safe and effective. It should be noted that in the control group was randomized controlled trial with a placebo control group, non-randomized placebo-controlled trial of statistical results are not the same, and we look forward to the placebo control group is the emergence of a large multi-center RCT. |
PDF Full Text Request